AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
常見問題
AgomAb Therapeutics NV 今天的股價是多少?▼
M5E.F 目前價格為 €6.65 EUR,過去 24 小時下跌了 -5.67%。在圖表上更密切關注 AgomAb Therapeutics NV 股票的表現。
AgomAb Therapeutics NV 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Frankfurt Exchange 交易所,AgomAb Therapeutics NV 的股票以代號 M5E.F 進行交易。
AgomAb Therapeutics NV 的市值是多少?▼
今天 AgomAb Therapeutics NV 的市值為 327.5M
AgomAb Therapeutics NV 會發放股息嗎?▼
是的,M5E.F 的股息每 年度 發放一次。每股最新股息為 2.22 。截至今日,股息殖利率(FWD)% 為 0%。
AgomAb Therapeutics NV 有多少名員工?▼
截至 2026年11月1日,公司共有 62 名員工。
AgomAb Therapeutics NV 位於哪個產業?▼
AgomAb Therapeutics NV從事於Health & Wellness產業。
AgomAb Therapeutics NV 何時完成拆股?▼
AgomAb Therapeutics NV 最近沒有進行任何拆股。
AgomAb Therapeutics NV 的總部在哪裡?▼
AgomAb Therapeutics NV 的總部位於 瑞典 的 Antwerp。